Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

New England Journal of Medicine

Volumn 358, Issue 2, 2008, Pages 140-151

  Bissler, John J ^a   McCormack, Francis X ^b   Young, Lisa R ^a,b   Elwing, Jean M ^b   Chuck, Gail ^a   Leonard, Jennifer M ^a   Schmithorst, Vincent J ^a   Laor, Tal ^a   Brody, Alan S ^a   Bean, Judy ^a   Salisbury, Shelia ^a   Franz, David N ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALLERGIC RHINITIS; ANGIOMYOLIPOMA; ANXIETY; APHTHOUS ULCER; ARTICLE; BRAIN DAMAGE; BREAST CYST; BRONCHITIS; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DEMENTIA; DEMOGRAPHY; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLANK PAIN; FOLLICULITIS; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEMATURIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOXIA; KIDNEY HEMORRHAGE; LEUKOPENIA; LUNG CYST; LUNG FUNCTION TEST; LYMPHANGIOLEIOMYOMATOSIS; MALE; MENSTRUAL IRREGULARITY; MIGRAINE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; SALIVARY GLAND DISEASE; SIDE EFFECT; SINUSITIS; STOMATITIS; THYROID PAPILLARY CARCINOMA; TUBEROUS SCLEROSIS; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS BLEEDING; BRAIN; GENETICS; KIDNEY DISEASE; LIVER DISEASE; LUNG; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ADULT; ANGIOMYOLIPOMA; BRAIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER DISEASES; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RESPIRATORY FUNCTION TESTS; SIROLIMUS; TUBEROUS SCLEROSIS;

EID: 38049169559     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa063564     Document Type: Article

References (35)

1. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol 2004;19:643-9.
2. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004;66:924-34.
3. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-8.
4. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000;97:6085-90.
5. Karbowniczek M, Astrindis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-82.
6. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24.
7. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
8. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
9. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
10. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-50.
11. Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002;11:525-34.
12. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 2000;57:662-5.
13. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173:105-11.
14. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-85.
15. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-8.
16. Chen AC, Sung WH, Wang PH, Sheu MH, Doong JL, Yuan CC. Correlation of three-dimensional tumor volumetry with cervical cancer prognostic parameters. Eur J Gynaecol Oncol 2002;23:401-4.
17. Mayr NA, Magnotta VA, Ehrhardt JC, et al. Usefulness of tumor volumetry by magnetic resonance imaging in assessing response to radiation therapy in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1996;35:915-24.
18. Mayr NA, Yuh WT, Taoka T, et al. Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol 2006;187:65-72.
19. Gylys-Morin VM, Graham TB, Blebea JS, et al. Knee in early juvenile rheumatoid arthritis: MR imaging findings. Radiology 2001;220:696-706.
20. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003;64:1035-45.
21. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
22. Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J Respir Crit Care Med 2003;167:1287.
23. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004;126:1867-74.
24. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991;66:792-6.
25. Herry I, Neukirch C, Debray MP, Mignon F, Crestani B. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007;18:76-7.
26. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006;48(3):e27-e29.
27. Dickinson M, Ruckle H, Beaghler M, Hadley HR. Renal angiomyolipoma: optimal treatment based on size and symptoms. Clin Nephrol 1998;49:281-6.
28. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8.
29. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304.
30. Brattström C, Wilczek HE, Tydén G, Böttiger Y, Säwe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998;30:3950-1.
31. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036-42.
32. Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002;36:1391-5.
33. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000;69:2085-90.
34. Kaplan MJ, Ellis CN, Bata-Csorgo Z, Kaplan RS, Endres JL, Fox DA. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999;135:553-7.
35. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78:264-8.